This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
by Zacks Equity Research
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
by Ahan Chakraborty
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
by Kinjel Shah
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
pharmaceuticals
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?
by Kinjel Shah
Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change
pharmaceuticals
Durable Goods Orders Decreased Less Than Expected
by Zacks Equity Research
Durable Goods Orders Decreased Less Than Expected
LLYPositive Net Change BMOPositive Net Change BNSNegative Net Change
finance medical pharmaceuticals
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
by Zacks Equity Research
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
CPRXNegative Net Change CRMDNegative Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
by Ahan Chakraborty
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pre-Markets in Red but Improving on New Data
by Mark Vickery
We appear to be bouncing around a bit more in recent trading days after a steadier level following August 2nd lows.
LLYPositive Net Change BMOPositive Net Change BNSNegative Net Change
banking earnings inflation interest-rate pharmaceuticals
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
by Zacks Equity Research
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
GSKNegative Net Change PFEPositive Net Change GILDNegative Net Change CVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
by Ekta Bagri
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
NVSPositive Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
by Zacks Equity Research
AbbVie is acquiring Gilgamesh's lead psychedelic drug bretisilocin for up to $1.2B, aiming to expand its depression treatment pipeline
JNJPositive Net Change BAYRYNegative Net Change ABBVPositive Net Change
pharmaceuticals
New Strong Sell Stocks for August 26th
by Zacks Equity Research
ASRT, BSM and JJSF have been added to the Zacks Rank #5 (Strong Sell) List on August 26, 2025.
JJSFNegative Net Change BSMPositive Net Change ASRTNegative Net Change
pharmaceuticals
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
by Zacks Equity Research
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.
NVSPositive Net Change BMYPositive Net Change LLYPositive Net Change RNAPositive Net Change
biotechs medical pharmaceuticals
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
by Zacks Equity Research
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
INOPositive Net Change CRMDNegative Net Change KNSAPositive Net Change PGENPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Take the Zacks Approach to Beat the Markets: WisdomTree, SkyWest & PepsiCo in Focus
by Santanu Roy
Zacks highlights gains for WisdomTree, SkyWest, and PepsiCo as its stock strategies deliver strong returns amid market volatility.
CATNegative Net Change JNJPositive Net Change HSYPositive Net Change PEPPositive Net Change MTDNegative Net Change SKYWNegative Net Change PRIMNegative Net Change SHOPNegative Net Change NOBLNegative Net Change CRDOPositive Net Change WTNegative Net Change HAFNNegative Net Change
computers construction consumer-staples finance industrial-products medical pharmaceuticals semiconductor transportation
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?
by Ekta Bagri
EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.
MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
by Kinjel Shah
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
JNJPositive Net Change AMGNNegative Net Change TEVAPositive Net Change KVUEPositive Net Change
pharmaceuticals
5 Blue-Chip Stocks to Buy as the Dow Achieves New Milestones
by Nalak Das
JPM, GS, JNJ, DIS, and MSFT are five blue-chip stocks that stand out with strong growth drivers and upgraded estimates as the Dow hits record highs.
GSNegative Net Change JPMNegative Net Change MSFTNegative Net Change JNJPositive Net Change DISNegative Net Change
consumer-discretionary finance pharmaceuticals tech-stocks
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
by Ekta Bagri
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
GSKNegative Net Change BMYPositive Net Change
biotechnology biotechs medical pharmaceuticals
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
by Zacks Equity Research
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
GILDNegative Net Change CVSPositive Net Change ANIPPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
by Kanishka Das
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
PFEPositive Net Change LLYPositive Net Change INCYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
by Kinjel Shah
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
pharmaceuticals
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
by Kinjel Shah
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change ABBVPositive Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk
by Zacks Equity Research
Healthcare stocks trade at a 30-year discount, with XLV showing signs of rebound as Buffett and hedge funds boost exposure.
REGNNegative Net Change UNHNegative Net Change NVONegative Net Change CVSPositive Net Change SPYNegative Net Change XLVNegative Net Change
pharmaceuticals